曾被资本狂热追捧的CAR-T疗法,在经历数年沉寂后近期再现融资暖流。科济药业与珠海软银日前达成的战略投资协议,引发市场对CGT(细胞与基因治疗)赛道的重新审视。资本破局:通用型技术打开估值空间2月26日,科济药业公告披露,旗下优恺泽生物完成珠海软银主导的8000万元战略融资,对应估值达10亿元。这家专注通用型CAR-T研发的平台企业,手握多个创新产品的中国区独家权益,此次融资标志着资本开始为尚处...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.